ImmuCell (NASDAQ:ICCC) Shares Cross Above Two Hundred Day Moving Average – Here’s What Happened

ImmuCell Corporation (NASDAQ:ICCC) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $6.59 and traded as high as $10.20. ImmuCell shares last traded at $10.12, with a volume of 33,471 shares.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

ImmuCell Stock Performance

The stock’s 50-day simple moving average is $7.60 and its 200 day simple moving average is $6.59. The company has a quick ratio of 2.60, a current ratio of 4.82 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $91.59 million, a price-to-earnings ratio of -168.64 and a beta of 0.50.

ImmuCell (NASDAQ:ICCC) last posted its earnings results on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.16. The firm had revenue of $10.36 million during the quarter, compared to analysts’ expectations of $5.40 million. ImmuCell had a negative return on equity of 1.88% and a negative net margin of 1.82%.

Institutional Trading of ImmuCell

A number of large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after buying an additional 2,907 shares in the last quarter. Steadtrust LLC boosted its position in shares of ImmuCell by 79.1% in the fourth quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock valued at $349,000 after acquiring an additional 25,070 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of ImmuCell by 3.2% in the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after acquiring an additional 1,749 shares in the last quarter. Mesirow Financial Investment Management Inc. increased its position in ImmuCell by 199.6% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after acquiring an additional 24,303 shares during the period. Finally, Militia Capital Management LLC acquired a new stake in ImmuCell in the 1st quarter worth about $114,000. Institutional investors and hedge funds own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.